Charles River to Acquire Cognate BioServices
We are pleased to announce plans to acquire Cognate BioServices, a premier cell and gene therapy contract development and manufacturing organization (CDMO), and Cobra Biologics, its gene therapy division. The planned acquisition will establish Charles River as a leading scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from early research and discovery through CGMP production.
Cognate BioServices offers comprehensive manufacturing solutions for cell therapies, as well as for production of plasmid DNA for gene therapies from their Cobra Biologics locations, and other inputs in the CDMO value chain: therapeutic proteins, microbiota, and viral vectors. Cognate has extensive experience producing various cell types and technologies used in cellular immunotherapy and immuno-oncology, regenerative medicine, and advanced cell therapy.
Combined with our integrated portfolio of manufacturing support services, including biologics testing, cell supply, and safety testing this acquisition will expand Charles River’s scientific capabilities into the emerging, high-growth cell and gene therapy CDMO sector, establishing a comprehensive solution from discovery and non-clinical development through CGMP manufacturing in advanced drug modalities.